Edition:
United States

Exelixis Inc (EXEL.O)

EXEL.O on Nasdaq

21.37USD
27 Mar 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$21.37
Open
--
Day's High
--
Day's Low
--
Volume
5,862
Avg. Vol
5,476,904
52-wk High
$23.49
52-wk Low
$3.64

Latest Key Developments (Source: Significant Developments)

Exelixis' cabozantinib granted orphan drug designation
Monday, 6 Mar 2017 09:04am EST 

Exelixis Inc : Exelixis' cabozantinib granted orphan drug designation for the treatment of hepatocellular carcinoma .Exelixis inc - exelixis has guided that data from trial are expected in 2017.  Full Article

Exelixis announces clinical trial collaboration with Roche
Monday, 27 Feb 2017 06:59am EST 

Exelixis Inc : Exelixis announces clinical trial collaboration with Roche to evaluate cabozantinib and atezolizumab in locally advanced or metastatic solid tumors . Exelixis Inc - expect to begin patient enrollment mid-year 2017 .Exelixis - study will evaluate potential of this combination in multiple solid tumors, including advanced renal cell carcinoma, urothelial carcinoma.  Full Article

Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab
Friday, 17 Feb 2017 05:02pm EST 

Exelixis Inc : Exelixis announces phase 1 trial results for cabozantinib in combination with nivolumab with or without ipilimumab in refractory metastatic urothelial carcinoma and other genitourinary tumors . Exelixis Inc - Recommended doses for ongoing expansion cohorts and future potential trials identified for doublet and triplet combinations .Exelixis - Data from Part II also demonstrate that using cabozantinib with two immunotherapy agents is well-tolerated with promising early activity.  Full Article

Genentech withdraws counterclaim against Exelixis in JAMS arbitration​
Monday, 9 Jan 2017 05:13am EST 

Exelixis Inc : Update on dispute between Exelixis and Genentech, a member of the Roche group . Exelixis relieved of $18.7 million of disputed costs . Genentech withdrew counterclaim against company in ongoing JAMS arbitration concerning "alleged breaches of parties' collaboration agreement" . Genentech's action does not address claims related to its clinical development, pricing and promotional costs for COTELLIC in United States .Genentech has not confirmed how it will allocate promotional costs with respect to collaboration's promotion of other combination therapies.  Full Article

BRIEF-Exelixis and Ipsen amend exclusive licensing agreement for commercialization,development of Cabozantinib to include Canada
Wednesday, 21 Dec 2016 01:18am EST 

Exelixis Inc : Press release - Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of cabozantinib to include canada . Exelixis - Amendment enhances productive year with Cabometyx regulatory approvals and commercial launches in United States and European Union . Says Exelixis to receive $10 million upfront payment, with subsequent regulatory and commercial milestones . Exelixis and Ipsen amend exclusive licensing agreement for the commercialization and development of Cabozantinib to include Canada . Says Ipsen is currently initiating launch of Cabometyx in EU .Says regulatory filing in canada is expected in 2017, with regulatory approval anticipated in early 2018.  Full Article

Exelixis announces Q3 and YTD 2016 financial results
Thursday, 3 Nov 2016 04:07pm EDT 

Exelixis Inc : Exelixis announces third quarter and year to date 2016 financial results and provides corporate update . Q3 loss per share $0.04 . Q3 revenue $62.2 mln versus $9.9 mln . Q3 revenue view $45.5 mln -- Thomson Reuters I/B/E/S .Q3 earnings per share view -$0.12 -- Thomson Reuters I/B/E/S.  Full Article

Exelixis says entered privately negotiated exchange agreements with certain holders
Monday, 22 Aug 2016 08:54am EDT 

Exelixis Inc : Entered into privately negotiated exchange agreements with certain holders of 4.25 pct convertible senior subordinated notes due 2019 . Holders agreed to exchange an aggregate principal amount of approximately $71.3 million of notes held by them . Exchange for an aggregate of approximately 13.4 million shares of the company’s common stock Source: (http://bit.ly/2bbqXzk ) Further company coverage: [EXEL.O] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Exelixis Q2 loss per share $0.16
Wednesday, 3 Aug 2016 04:06pm EDT 

Exelixis Inc : Exelixis announces second quarter and year to date 2016 financial results and provides corporate update . Q2 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S . Q2 revenue view $16.4 million -- Thomson Reuters I/B/E/S . Q2 loss per share $0.16 . Q2 revenue $36.3 million versus $8.0 million .Says is refining its guidance that operating expenses for full year 2016 will be between $250 million and $270 million.  Full Article

EU Medicines Agency recommends approval of two new cancer drugs
Friday, 22 Jul 2016 07:21am EDT 

EU Medicines Agency : EU medicines agency recommendations for july 2016 . Recommends approval of Exelixis Inc’S cabozantinib to treat advanced renal cell carcinoma .Recommends Approval Of Baxter International Inc’S Irinotecan to treat pancreatic cancer.  Full Article

Exelixis, Ipsen post results from advanced renal cell carcinoma study
Monday, 6 Jun 2016 07:30am EDT 

Exelixis Inc : Exelixis and its partner Ipsen announce positive overall survival results from subgroup analyses of phase 3 trial of CABOMETYX(tm) (cabozantinib) tablets in advanced renal cell carcinoma at 2016 ASCO annual meeting .Additional data from pivotal meteor trial underscore clinically meaningful benefit of CABOMETYX across subgroups of patients.  Full Article

More From Around the Web

BRIEF-Exelixis' cabozantinib granted orphan drug designation

* Exelixis' cabozantinib granted orphan drug designation for the treatment of hepatocellular carcinoma